Today, Islamic art is still being carved into the landscape of AlUla. In 2022, Desert X AlUla brought together acclaimed international artists to create monumental works amid the red sandstone ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

(Reuters) - British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any ...

Credit: CeltStudio/Shutterstock. Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK‘s new drug application (NDA) for Blenrep (belantamab mafodotin) to treat patients ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

An analysis of data from the phase 2 portion of the trial showed the primary efficacy objective had not been met. A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures. GSK and iTeos ...

At the European Society for Medical Oncology (ESMO) Congress 2024, GSK and iTeos finally provided the first data reveal of their TIGIT inhibitor, belrestotug, in combination with Jemperli (dostarlimab ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...